Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Terminated 6Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 77Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 18Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Recurrence 7Smoldering Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Lymphoma 4Lymphoma, Non-Hodgkin 3Plasmacytoma 2Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Neurologic Manifestations 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Whole-Body Irradiation 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Busulfan 5Melphalan 4Etoposide 4Cytarabine 4Azacitidine 4AP 1903 reagent 4ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Cyclosporine 3venetoclax 2pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Lenalidomide × Clear all
NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡